Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Hepatic Arterial Infusion
01
Overview
This refers to a specific clinical trial regimen evaluated at The University of Texas M.D. Anderson Cancer Center for the treatment of advanced solid tumors with liver metastases. The protocol utilizes a localized delivery method known as hepatic arterial infusion (HAI) for oxaliplatin, a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit replication. This targeted delivery to the liver is combined with a systemic chemotherapy backbone consisting of 5-fluorouracil (5-FU), leucovorin, and the anti-VEGF monoclonal antibody bevacizumab. Depending on the patient's K-RAS mutational status, the anti-EGFR antibody cetuximab may also be included. The regimen is designed to maximize the concentration of chemotherapy reaching liver tumors while utilizing systemic agents to address potential extrahepatic disease.
- Other names
- HAI Oxaliplatin combination therapyHepatic Arterial Infusion of Oxaliplatin with systemic chemotherapyoxaliplatin-M.D. Anderson Cancer Center-liver metastasis
02
Targets
TS (Thymidylate synthase)DNAEGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + 5-fluorouracil + leucovorin + bevacizumab + cetuximab.